STEM CELL-DERIVED LYOPHILIZED EXOSOME-BASED PERSONALIZED COSMETIC PRODUCT AND ITS PRODUCTION METHOD
Patent Information
- Application Number
- TR202612536
- Authority / Receiving Office
- TR · TR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-07-27
- Publication Date
- 2026-08-21
Smart Images
Figure 00000019_0000
Abstract
Description
1 TARIFF STEM CELL-DERIVED LYOPHILIZED EXOSOME-BASED PERSONALIZED COSMETIC PRODUCTS AND THEIR PRODUCTION METHODS TECHNICAL AREA 5 The invention describes a personalized device for topical application to the skin or scalp. It is related to cosmetic products. The invention describes a personalized device for topical application to the skin or scalp. It relates to the production method of the cosmetic product. 10 STATE OF THE ART In the field of cosmetic and aesthetic applications, skin rejuvenation and enhancing anti-aging effects. For many years, various active ingredients and applications have been used to revitalize hair follicles. methods are used. The commonly known approach in the current technique is hyaluronic acid, 15 containing components such as vitamin complexes, peptides, antioxidants, and plant extracts. It is based on the topical application of cosmetic products with standard formulations. This The products provide hydration to the skin's surface, support barrier function, and treat superficial fine lines. While it offers limited benefits such as reducing the appearance of lines, its effects are mostly minimal. It remains limited to the epidermal layer and does not reach the dermis or cellular level. (Source 20) A large portion of the products in question reflect genetic, epigenetic, and metabolic differences between individuals. Because it was developed with a general usage principle that completely disregards the issue, the resulting cosmetic It is inevitable that the effect will vary significantly from person to person. This This situation constitutes one of the fundamental technical limitations of current cosmetic approaches, and especially targeted at chronic skin problems or age-related degenerative changes 25 It prevents it from being managed. In recent years, bioactive molecules that play a critical role in cellular communication and their intercellular delivery have become increasingly important. Techniques for using exosomes, which facilitate transport, in cosmetic and regenerative applications. This has come to the forefront. In current practices, exosomes are generally allogeneic or autologous. 30 It is isolated from the supernatant of mesenchymal stem cell cultures and is biologically active. It is evaluated in terms of content. However, there are two main technical problem areas at this point. It contains. Firstly, there is almost invariable need for exosomes to be delivered to the target tissue. invasive procedures such as injections, microneedling, mesotherapy, or fractional laser pre-treatment This involves resorting to micro-invasive methods. These methods involve the delivery of exosomes to the stratum corneum 35 The aim is to enable it to penetrate the barrier and reach deeper dermal layers, 2 Risks of pain during application, bleeding, infection, and post-inflammatory reactions. Significant issues include undesirable tissue responses such as hyperpigmentation and a significant decrease in patient comfort. This brings with it disadvantages. Furthermore, these invasive techniques are often localized. This requires the use of anesthetic or analgesic agents, which in turn necessitates the application protocol. complicates things, increases costs, and makes the procedure only possible in clinical settings and with trained healthcare professionals. It limits its personnel. The second main problem is that almost every isolated exosome... time in liquid form, usually in phosphate-buffered saline or cell culture supernatant The purpose is storage and utilization. The structural integrity and biological properties of exosomes in this liquid form... activities such as temperature fluctuations, freeze-thaw cycles, and enzymatic degradation It is extremely sensitive to environmental factors. This situation makes the current technique based on exosome-based 10 the products have an extremely short shelf life, due to storage at low temperatures. due to the need, their portability becoming almost impossible, and the distribution chain This leads to the lack of a guarantee that they will maintain their biological activity throughout the process. This stability... and logistical constraints make exosomes widely and commercially viable in the cosmetics industry. This technically prevents it from becoming an active ingredient. 15 These three main, deep and interconnected problems in current technology, namely standard cosmetics The superficial and non-personalized effect of the products, the invasiveness of potent biological agents such as exosomes. the inability to effectively administer liquid exosome formulations without methods and the excessive Stability and logistical constraints necessitate the development of a new technical solution in this field. This is where the present invention comes in, aiming to fundamentally solve these technical problems. It offers an innovative approach. The invention isolates biological material from the individual's own biological material. A personalized and biocompatible active ingredient is created using exosomes. forming the component basis, isolated exosomes in the presence of a cryoprotective agent Thanks to the lyophilization process, it remains stable even at room temperature and has a long shelf life of 25. a lyophilized exosome that is portable and can be activated by rehydration at the time of use. the form is being developed and these stabilized lyophilized exosomes are applied entirely topically. by integrating it into an applicable dermocosmetic carrier matrix for injection or Effectively targets the tissue without the need for any invasive procedures such as microneedling. This makes it feasible. In this way, the invention utilizes three fundamental principles currently available in the existing technology. an advanced cosmetic product that eliminates limitations simultaneously and synergistically. It offers technical solutions. Patent document number CN110129265A describes an umbilical cord mesenchymal stem cell. exosome, its preparation method and the application of exosome to cosmetic product 35 It is mentioned. The invention involves a substance secreted by mesenchymal stem cells and stem cells exosomes possessing the characteristics of miR-525-3p high-expression umbilical cord mesenchymal 3 The use of stem cell exosomes in cosmetic products against skin aging. This provides. Unlike the existing invention, in this document the exosomes are of allogeneic origin. It is not obtained from the individual's own biological material; exosomes are stabilized by lyophilization. to be integrated into a cosmetic carrier matrix for non-invasive topical application or application It is not foreseen that this will happen. 5 Patent document number US11723931B2 describes induced pluripotent stem cell-derived... Treatment of skin diseases involving mesenchymal stem cells and exosomes derived from them. The invention refers to a cosmetic composition used for the prevention or treatment of certain conditions. These cells, called induced pluripotent stem cell-derived mesenchymal stem cells, are 10 or exosomes isolated from them, compared to conventional mesenchymal stem cells By providing improved immunomodulatory function, it can be used in the treatment of skin diseases. It involves the use of exosomes. Unlike the current invention, in this document, exosomes are used in the individual. It is not obtained from its own autologous source, stabilization by lyophilization is not foreseen, and There are no limitations regarding the method of application of the product, whether invasive or non-invasive. 15 It is not being brought. Patent document CN120478253A describes a subgroup of mesenchymal stem cell exosomes. S2 is used in the preparation of cosmetic compositions or drugs for skin improvement. It is mentioned. The invention relates to the cosmetic composition or drug in question being divided into 20 subgroups. to provide a more pronounced and stable skin improvement effect compared to undifferentiated exosomes This ensures that it contains this subgroup as the sole active ingredient. Unlike the present invention, this The document describes the stabilization of exosome subgroup S2 via lyophilization, a cosmetic carrier. for integration into the matrix or for topical non-invasive application via rehydration. There are no elements such as activation. 25 Patent document number CN115404211A describes a stem cell derived from umbilical cord mesenchymal stem cells. The exosome and its cosmetic application are discussed. The invention relates to high CCR5 levels. mesenchymal stem cells secreted by expressed umbilical cord mesenchymal stem cells Cell-derived exosomes are 30% more numerous than traditional mesenchymal stem cell-derived exosomes. By more effectively inhibiting the proliferation of fibroblasts in human keloid tissue, the cells... It enables him to encourage his death. Unlike the current invention, in this document Exosomes originate not from the individual's own biological material, but from an allogeneic umbilical cord source. It is obtained and used as a carrier matrix for lyophilization or non-invasive topical application. Integration is not foreseen. 35 4 Patent document number CN215603742U describes an exosome derived from mesenchymal stem cells. A bottle designed to hold cosmetic liquid, sealing ring, operating tube, and outlet. The text describes a liquid storage and dispensing system that includes a plate and an outlet chute. The invention enables the user to move elastic fabric via a rotating vertical shaft on the device. by adjusting the internal volume of the outlet chute, thus dispensing the cosmetic liquid 5 It enables the quantity to be controlled. Unlike the existing invention, in this document related to the biological source of exosomes, isolation method, stabilization or personalization. There is no technical content; it is simply a description of a packaging and dispensing apparatus. is being done. Patent document number CN120860177A describes a cosmetic anti-aging mesenchymal stem cell. The composition of the exosome is mentioned. The invention involves a therapeutically effective amount of mesenchymal exosome. A subcutaneous absorption enhancer and antioxidant stabilizer along with stem cell-derived exosome. In addition to a functional carrier, it contains small molecule peptides and plant-derived antioxidants. and contains synergistic active components such as hyaluronic acid, and is synergistically active with the exosome. It enables the components to be combined using phospholipid bilayer fusion technology. Unlike the current invention, in this document exosomes are obtained from the individual's own autologous source. It is not being processed; instead of stabilization by lyophilization, use in liquid form is foreseen and topical application is recommended. In addition to integration into the carrier matrix for the application, activation is achieved through rehydration. There is no element. 20 Patent document number CN110151678A describes a substance made from fatty tissue used to reduce wrinkles. a stem cell-derived mesenchymal stem cell exosome containing plant extract from exosome composition and a cosmetic product containing this composition It is mentioned. The invention involves elastase and 25 of the fat-derived mesenchymal stem cell exosome. It is shown to have an effect against skin aging thanks to its collagenase inhibitory activity, and also It also ensures that herbal extracts are absorbed by the skin at the same time. Available Unlike the invention, in this document exosomes are not obtained from the individual's own source. Derived from allogeneic adipose tissue source, stabilized by lyophilization and non-invasive. Carrier matrix integration for topical application is not foreseen. 30 Patent document CN114106205A describes a mesenchymal root modified with TRADD. cells are cultured and then microfluidic technology is used to extract adipose tissue-derived cells. palmitoyl-7 peptide and TH peptide with exosomes extracted from mesenchymal stem cells 35 from a cosmetic composition created by assembling a compound polypeptide It is stated that the invention provides exosomes with high purity and strong targeting capabilities obtained by this method. and it has penetration properties and is anti-aging, antioxidant, and wound healing. It includes providing therapeutic and anti-inflammatory effects. Unlike the current invention, this The document states that exosomes are not from the individual's own biological material, but from allogeneic adipose tissue. It is obtained from its source and used in liquid form instead of stabilization by lyophilization. There is no anticipated or personalized autologous approach. Patent document number CN117165520A describes mesenchymal stem cells derived from human fat. a mesenchymal stem cell exosome prepared by stimulated secretion, containing this exosome a gel formulation and its use in epidermal trauma and blemish removal It is stated that the invention involves the antioxidant activity and tyrosinase inhibitory effect of exosome feedstock. It has activity, the gel formulation has long-term release and ultraviolet radiation 10 It includes providing protection and also supporting wound healing. Different from the current invention. Specifically, in this document, exosomes are not obtained from the individual's own autologous source but are allogeneic. Derived from adipose tissue, it is processed into a liquid gel form instead of stabilization by lyophilization. A base-based system is used, and there is no element of individual personalization. Patent document number CN107217034A describes a human umbilical cord mesenchymal stem cell. The invention describes the source of exosomes, the method of obtaining them, and their application. Interferon, erythropoietin, and platelet-derived growth factor BB were added to the cell culture medium. The exosomes obtained by adding these elements have a phospholipid bilayer structure and contain microribonucleic acid, messenger ribonucleic acid, deoxyribonucleic acid, and nucleic acids 20 By entering endothelial cells, it causes them to multiply and form a network-like structure. It ensures that it encourages. Unlike the current invention, in this document, exosomes are used by the individual. It is obtained not from the patient's own biological material, but from an allogeneic umbilical cord source. Cosmetic carrier matrix for stabilization by lyophilization or non-invasive topical application. Integration is not foreseen. 25 Patent document number CN111643442A describes an umbilical cord mesenchymal stem cell exosome. the solution contains a mixture of licorice root exosome, lentinan, tocopherol, and sodium hyaluronate. The text describes exosome cosmetic liquid and its preparation method. The invention relates to this... The improvement of fine lines on the face as a result of applying the mixture using the microneedle method 30 and includes effects such as skin tone lightening. Unlike the present invention, In this document, exosomes are not obtained from the individual's own source; the product is obtained using microneedles, etc. It is applied via an invasive method, stabilization by lyophilization is not foreseen, and it is topical. For non-invasive application, the liquid is injected directly into a carrier matrix instead of being integrated within it. The usage is in the form of 35. 6 Patent document CN107245472A describes the lyophilization of a human mesenchymal stem cell exosome. The method of preparing and using the powder is described. The invention concerns humans. Culture, purification, and passage of mesenchymal stem cells, followed by large-scale processing of these cells. stimulation of scale-based functional exosome synthesis and secretion, the resulting exosomes Concentration by ultrafiltration and subsequent cold storage to lyophilized powder form 5 It includes the stages of transformation. Unlike the present invention, in this document Exosomes are not derived from the individual's own biological material, but from allogeneic mesenchymal stem cells. Although obtained from cultures and lyophilized, they are suitable for non-invasive topical application. Integration into cosmetic carrier matrix or rehydration prior to use No activation is foreseen. 10 Patent document CN115287258A describes an exosome of a mesenchymal stem cell extract. culturing the cells in serum-free medium, then collecting the culture cell supernatant and a product obtained by dissolving ultrasonically fragmented cells in physiological saline. The method of preparation is described. The invention involves tissue preparation of exosomes obtained in this way. 15 It promotes skin repair, regulates immune function, increases skin moisture, and reduces skin damage. It ensures that it repairs the barrier. Unlike the current invention, in this document, exosomes It is obtained from allogeneic sources, not from the individual's own autologous source, through lyophilization. Instead of stabilization, it is intended for use in liquid form and is cosmetic for topical application. There is no carrier matrix integration. 20 Patent document number US11865141B2 describes pretreatment with interferon-gamma. induced pluripotent stem cell-derived mesenchymal stem cells and those derived from them a substance containing exosomes, used for the treatment, prevention, or management of skin diseases The cosmetic composition is discussed. The invention is based on 25% of cosmetics pre-treated with interferon-gamma. These cells, called induced pluripotent stem cell-derived mesenchymal stem cells, or exosomes isolated from them, compared to conventional mesenchymal stem cells It includes providing enhanced immunoregulatory function. Different from the current invention. Specifically, in this document, exosomes are not from the individual's own autologous source, but from allogeneically induced sources. Obtained from pluripotent stem cells, stabilized by lyophilization or non-invasive 30 Integration into a carrier matrix for topical application is not foreseen. Patent document number CN106913583A describes an exosome derived from human mesenchymal stem cells. The method of preparing a bioactive preparation is described. The invention involves the preparation of chitosan in dilute acetic acid. Obtaining a chitosan solution by dissolving it in acid, exosome lyophilized powder, 35 Glucosaminoglycans and hyaluronic acid are dissolved in glycerin to form an exosome solution. brought in, then this exosome solution is drop-dropped into the chitosan solution containing the exosome. 7 Formation of chitosan nanoparticle suspension and precipitation after centrifugation It involves the processes of collecting and drying. Unlike the present invention, in this document Although lyophilized exosomes are used, these exosomes are obtained from the individual's own autologous source. instead of being integrated into a cosmetic carrier matrix for topical application Nanoparticle formulation is envisioned and activation by rehydration prior to use 5 It does not contain any element. Patent document number CN111184679A describes an umbilical cord mesenchymal stem cell. exosome, moisturizer, thickener, chelating agent, emollient, emulsifier, skin The invention refers to a crack repair preparation containing a regulator and a solvent. This invention is based on 10 The preparation is safe and effective, repairing and fading stretch marks, and softening the abdominal skin. It has significant effects in thinning and increasing skin firmness and moisture levels. It includes. Unlike the current invention, in this document, exosomes are the individual's own biological cells. It is obtained not from its own material, but from an allogeneic umbilical cord source, by lyophilization. Integration into a carrier matrix for stabilization or non-invasive topical application 15 Furthermore, there is no personalization element. Patent document number CN117377754A describes the use of mesenchymal stem cells derived from adipose tissue. The invention refers to an exosome production stimulant that promotes exosome production. Exosome 20 from lipid-derived mesenchymal stem cells cultured in serum-free medium to increase its production, epidermal growth factor, interleukin-1 beta and trehalose containing, preferably This allows the use of a composition that does not contain stem cell growth factors. Currently available Unlike the invention, this document aims to increase the production of exosomes, Obtaining exosomes from the individual's own source, stabilizing them by lyophilization, or Any technical content regarding integration into cosmetic product formulation 25 It is not available. Patent document number KR102360077B1 describes a mesenchymal root originating from the umbilical cord. Skin improvement, wrinkle treatment containing exosome isolated from cells as an active ingredient. Improvement, regeneration, increased flexibility, moisturizing, barrier strengthening, anti-inflammatory or 30 The discussion concerns a cosmetic composition that exhibits a whitening effect. The invention relates to this... Exosomes have damage mitigation, wrinkle improvement, regeneration, increased elasticity, and moisturizing properties. Skin improvement through barrier strengthening, anti-inflammatory or whitening effects, inflammatory skin It enables the prevention of diseases or their use as a pharmaceutical component. Unlike the current invention, in this document, exosomes are derived from the individual's own autologous source. 35 No, it is obtained from an allogeneic umbilical cord source, stabilized by lyophilization or 8 Any techniques regarding carrier matrix integration for non-invasive topical application No regulations are foreseen. Patent document number CN121177187A describes the use of deer bone marrow mesenchymal stem cells. The membrane surface of the obtained exosomes was oriented using CD63 antibody. 5 By modifying the cells, targeted delivery to epidermal basal layer stem cells was achieved. also whitening active polypeptide with phospholipid and poly(N-isopropylacrylamide) The phase change is controlled by loading the resulting temperature-sensitive nano-liposomes into them. The text refers to a stem cell exosome polypeptide complex that triggers release. Unlike the invention, in this document, exosomes are not from the individual's own source, but allogeneic 10 It is obtained from deer bone marrow source, and instead of stabilization by lyophilization, it is in liquid form. Emulsion formulation is used, and an autologous personalization element is incorporated that is specific to the individual. It is not available. Patent document number CN117257714A describes the combination of plant-derived exosomes with human stem cells. The text refers to a cosmetic composition in which exosomes of various origins are combined. The invention involves the derivation of plant exosomes from three to seven, respectively, red rose, geranium, short-stemmed cap grass, and ground cover. that it is obtained from barrel banana and lily of the valley, and that human-derived stem cell exosomes are from placental stem cell exosome and umbilical cord mesenchymal stem cell exosome It includes the formation of exosomes. Unlike the current invention, in this document, exosomes are formed from the individual's own 20 Obtained not from an autologous source, but from allogeneic sources such as placenta and umbilical cord. It is being processed, stabilization by lyophilization is not foreseen, and it is for non-invasive topical application. Instead of carrier matrix integration, a direct composition mixture is offered. Patent document number JP2021116228A describes 25 exosomes containing mesenchymal stem cell-derived exosomes. The invention refers to an antioxidant stress agent, a cosmetic preparation, and a pharmaceutical product. Exosomes derived from mesenchymal stem cells have an antioxidant effect, thus reducing oxidative stress. It enables its use in the prevention or treatment of stress-related skin damage. Unlike the current invention, in this document, exosomes are derived from the individual's own biological material. not obtained, stabilization by lyophilization or non-invasive topical application 30 Integration into the cosmetic carrier matrix is not foreseen; only the antioxidant effect is intended. that is the focus. Patent document CN113521306A describes a transfersome-exosome membrane fusion. The method of preparing the preparation is discussed. The invention is mesenchymal stem cell 35 Extraction and isolation of the exosome, a small molecule peptide-loaded carrier preparation, small molecule peptide loaded with a peptide modified to enhance subcutaneous absorption. 9 Construction of transfersome-exosome membrane fusion transporter and plant essential oil gel It includes the preparation stages, and this fusion preparation is similar to traditional liposomes. It has a higher deformation capability and superior subcutaneous absorption effect compared to others. This ensures that, unlike the current invention, exosomes are the individual's own. It is obtained from allogeneic mesenchymal stem cells, not autologous, and processed through lyophilization. Instead of stabilization, liquid form membrane fusion technology is used, and personalization is achieved. It does not contain any element. Patent document number CN120713821A describes umbilical cord mesenchymal stem cells, type I. collagen, chitosan-hyaluronic acid microspheres, plant stem cell extract, and 10 liposomes The discussion concerns a composition containing an exosome. The invention involves component biomimetics and distribution. Through system innovation and multi-target synergy, it combines security, efficiency, and user experience. by offering a combined competitive advantage in the high-end anti-aging cosmetics market. Unlike the current invention, in this document, exosomes are found in an individual's own biological system. It is presented in allogeneic liposome-wrapped form, not from its own material, and stabilized by lyophilization. 15 It is not foreseen, and there is no autologous personalization approach. Patent document number CN111544369A describes mesenchymal stem cell exosomes, deionized water, glycerol, mineral oil, carboxymethyl cellulose, polyoxyethylene lanolin, cetyl alcohol, Ethylenediaminetetraacetic acid disodium salt, red myrrh, also lily extract, sage 20 A facial beautifying product containing extract, seaweed extract, and gingko extract. The composition is discussed. The invention claims that this composition unlocks the skin's own potential. It activates, repairs epidermal cells and promotes epidermal cell renewal. This ensures that, unlike the current invention, exosomes are the individual's own. It is obtained from allogeneic mesenchymal stem cells, not autologous, and processed through lyophilization at 25°C. Regarding carrier matrix integration for stabilization or non-invasive topical application. There are no technical regulations in place. Patent document number KR102923070B1 describes mesenchymal stem cells derived from Wharton's jelly tissue. Exosomes isolated from cells can be economically produced with high yield and high purity. 30 a preparation method that enables its production and includes exosomes produced by this method The cosmetic composition is discussed. The invention relates to mesenchymal tissue derived from Wharton's jelly. Exosomes obtained from the culture medium composition of stem cells yield high efficiency and high It enables its production economically by separating it in a pure form. Unlike the current invention, In this document, exosomes are not from the individual's own autologous source, but from allogeneic Wharton's gel 35 tissue is obtained from the source, stabilization of exosomes by lyophilization and non- instead of integration into a cosmetic carrier matrix for invasive topical application It is envisioned that the product will be isolated directly from the culture medium and used in liquid form, in addition to... Activation by lyophilization in the presence of a cryoprotectant agent and rehydration prior to use. Such elements are not present. Studies have shown that in the field of cosmetic and aesthetic applications, skin rejuvenation and anti-aging 5 Mesenchymal stem cells are used to enhance the anti-hair loss effects and revitalize the hair follicle. Various technical approaches have been developed for the use of derived exosomes. In the current technique, exosomes are obtained from allogeneic umbilical cord, adipose tissue, bone marrow, or induced coagulation. Isolated from sources such as pluripotent stem cells and incorporated into cosmetic compositions. Furthermore, in some applications, exosomes are converted into lyophilized powder form or 10 It is known that microneedles are applied using invasive methods such as injections. However, this is currently the case. There are three fundamental shortcomings common to all approaches that remain technically unresolved. There are. Firstly, in all existing applications, exosomes are used by the individual themselves. It is obtained from allogeneic sources, not from biological material, and this makes it personal. biological differences are not taken into account, and therefore the cosmetic effect obtained varies from person to person by 15 This causes it to vary from person to person. Secondly, in some existing practices... Even if exosomes are lyophilized and presented in powder form, these lyophilized powders cannot be applied directly to the skin. integration with a cosmetic carrier matrix that will allow its application to the surface or Factors such as activation through rehydration before use are not foreseen, also To preserve the structural integrity and biological activity of exosomes during the lyophilization process. 20 The use of a cryoprotective agent is not mentioned. Third and most importantly, the current In almost all applications, microneedles are used to deliver exosomes to the target tissue. Invasive methods such as injections or mesotherapy are necessarily used, or these Methods are being suggested that exhibit similar biological efficacy to non-invasive topical application. No technical solution is offered to demonstrate how this can be achieved. The present invention addresses these three 25 an innovative system designed to simultaneously address fundamental technical deficiencies The invention presents a design primarily derived from the individual's own biological material, preferably peripheral blood. Fully personalized and superior biocompatibility through the use of isolated exosomes. It provides an active ingredient base that enables the treatment of conditions caused by allogeneically derived exosomes. It eliminates the problem of effect variability. Secondly, the invention isolates this autologous 30 lyophilization of exosomes in the presence of a cryoprotective agent such as trehalose or sucrose By undergoing this process, its structural integrity and biological activity are preserved, and it can be stored at room temperature. to obtain a lyophilized exosome form that remains stable for a long time, is portable and storable, These lyophilized exosomes are then supplemented with auxiliary active ingredients such as hyaluronic acid, peptides, and vitamins. by integrating it into a dermocosmetic carrier matrix that may contain the components, topical 35 preparing it for application, and also with a suitable rehydration solution before use. It offers the possibility of activation. Thirdly, and most critically, the invention, prepared in this way... 11 The personalized cosmetic product is applied directly to the skin without the need for any invasive procedures. This allows it to be applied topically to the surface or scalp, thus enabling the existing Injection, microneedling, or other methods deemed essential for the effective use of exosomes in this technique. Pain, risk of infection, tissue damage, and patient discomfort caused by methods such as mesotherapy. It completely eliminates all disadvantages such as those mentioned above. Therefore, the present invention, allogeneic 5 The three basic techniques are resource utilization, the need for invasive procedures, and stability limitations. By solving the problem together, we can achieve a clear and superior result compared to all comparable applications in current technology. They are separated in this way. Ultimately, the problems mentioned above, which cannot be solved with the current technology, are related to technical issues. 10 This has made it necessary to make an innovation in the field. A BRIEF DESCRIPTION OF THE INVENTION The invention is created by drawing inspiration from existing situations and aims to solve the aforementioned drawbacks. It aims to... 15 The aim of the invention is to create a personalized solution that takes into account the individual's unique biological characteristics. The aim is to describe cosmetic products and their production methods. Another aim of the invention is to provide a personalized solution that offers high biocompatibility and biological efficacy. The goal is to create cosmetic products. 20 Another objective of the invention is to preserve the structural integrity and biological activity of biologically active ingredients. The goal is to create a cosmetic product that provides protection. Another aim of the invention is to improve the stability and shelf life of the product, making it easier to store and transport. The goal is to create a simplified cosmetic product. Another aim of the invention is to provide topical applications without the need for invasive or micro-invasive procedures. The goal is to create a cosmetic product that can be applied in various ways. Another aim of the invention is to increase user comfort during application and to be application-dependent. The goal is to create a cosmetic product that reduces risks. Another aim of the invention is to promote skin regeneration, anti-aging care, and hair follicle activation. The goal is to create a personalized cosmetic product that can be used for this purpose. 35 12 Another aim of the invention is to create a repeatable, standardizable and industrial-scale product. The goal is to develop a viable production method. To fulfill the purposes described above, the invention involves the topical application of the product to the skin or scalp. It is a personalized cosmetic product designed for application. The cosmetic product is a biological... Isolated exosomes isolated from the sample were lyophilized in the presence of at least one cryoprotective agent. at least one form of lyophilized exosome obtained by processing and the aforementioned lyophilized exosome It contains at least one cosmetic carrier matrix in which the form is dispersed. The invention also relates to a method for producing a personalized cosmetic product. The production method consists of 10... - for the purpose of removing cellular debris and large particles from a biological sample. pre-processing, - an exosome isolated from a pre-processed biological sample using an exosome isolation unit. obtaining exosomes, - sterile filtration of the suspension containing isolated exosomes, 15 - Mixing isolated exosomes with at least one cryoprotective agent, - The resulting mixture is subjected to lyophilization to form a lyophilized exosome. obtaining, - the lyophilized exosome form must be added to at least one cosmetic carrier matrix and - 20% of the lyophilized exosome form is homogeneously distributed within the cosmetic carrier matrix. It includes the steps to obtain the final cosmetic product by distributing it. The structural and characteristic features and all the advantages of the invention are given in the figures below. The detailed explanation, written with references to figures, makes it clearer. This will be understood, and therefore the evaluation should also take these figures and detailed explanations into account. It must be done by taking 25. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows a schematic view of the personalized cosmetic product that is the subject of the invention. REFERENCE NUMBERS 30 1 - Biological Sample 2 - Exosome Isolation Unit 3 - Isolated Exosome 4 - Cryoprotective Agent 13 - Lyophilized Exosome Form 6 - Cosmetic Carrier Matrix 7 - Auxiliary Active Ingredient 8 - Cosmetic Products 9 - Rehydration Fluid 5 DETAILED DESCRIPTION OF THE INVENTION In this detailed description, the personalized cosmetic product (8) which is the subject of the invention and its production are described. The preferred structures of the method are solely for the purpose of better understanding the subject. It is explained. 10 Figure 1 shows the subject of the invention: stem cell-derived lyophilized exosome-based personalized cosmetics. (8) shows the schematic view of the product. The starting material for obtaining the personalized cosmetic product (8) which is the subject of the invention At least one biological sample (1) is used. Biological sample (1) is biological material from the individual. or can be obtained from suitable cellular sources. In the preferred application, biological 15 Sample (1) is peripheral blood taken from an individual. Biological sample (1) is plasma or serum belonging to an individual. However, biological samples (1) are obtained from mesenchymal stem cell cultures. The resulting cell culture supernatant can be used. Alternative applications of this invention may involve... Mesenchymal stem cells can originate from adipose tissue, bone marrow, or umbilical cord. At least one 20°C is required to separate exosomes from other cellular components in the biological sample (1). Exosome isolation unit (2) is used. Exosome isolation unit (2) is used for biological sample (1) After the removal of cellular debris and large particles, approximately 30-150 It enables the isolation of exosomes in the nm diameter range. At least one isolated exosome (3) is obtained from the biological sample (1) by means of the exosome isolation unit (2). Isolated exosomes (3) contain biologically active components that play a role in cellular communication. extracellular vesicles containing and the main active ingredient of the personalized cosmetic product that is the subject of the invention It constitutes a component of the isolated exosomes (3), which play a role in cellular communication. They may contain bioactive signaling molecules. The subject of the invention is personalized cosmetic products (8), stabilization of isolated exosomes (3) It contains at least one cryoprotective agent (4) for use. Cryoprotective agent (4), 30 Structural integrity and biological activity of isolated exosomes (3) during lyophilization It supports the protection of the cryoprotectant agent (4) preferably of disaccharide structure. It is a stabilizer. The preferred cryoprotectant agent in the application is trehalose or sucrose (4). Alternatively, mannitol or similar stabilizers may be used. 14 Drying of isolated exosomes (3) in the presence of cryoprotectant agent (4) resulted in at least one Lyophilized exosome form (5) is obtained. Lyophilized exosome form (5) is obtained from isolated exosomes. (3) It is the dry and stable form obtained by removing the water content. Lyophilized exosome form (5) is a form aimed at increasing the storability and transportability of isolated exosomes (3). The subject of the invention is a personalized cosmetic product (8) and also a homogeneous lyophilized exosome form (5) 5 It contains at least one cosmetic carrier matrix (6) in which it is distributed. Cosmetic carrier matrix (6) can be selected from pharmaceutical or dermocosmetic bases compatible with the skin. Cosmetics carrier matrix (6); can be in the form of cream, serum, gel, lotion or mask. Alternative Cosmetic carrier matrix in applications (6), a nanoparticle based carrier system, liposomal These carrier systems may include a structure or hydrogel system. These carrier systems are used to store isolated exosomes (3) 10 It can be used to support its transport and release. Cosmetic carrier matrix (6) may contain at least one auxiliary active ingredient (7). Auxiliary active component (7); from among hyaluronic acid, peptide complexes, vitamins and antioxidant components Vitamins can be selected. The most suitable vitamin is preferably chosen from among vitamin A, vitamin C, and vitamin E. It is one of the few. One or more of the aforementioned auxiliary active components (7) together 15 It can be used. Lyophilized exosome form (5), cosmetic carrier matrix (6) and if available by combining the auxiliary active ingredient (7) at least one final cosmetic product (8) is obtained The final cosmetic product (8) contains biologically specific ingredients and is applied to the skin surface or It is a personalized cosmetic product that can be applied topically to the scalp. The subject of the invention is the final cosmetic product (8) and also the lyophilized exosome form (5) 20 before use. together with at least one rehydration liquid (9) to ensure its rehydration. It can be used. Rehydration fluid (9), lyophilized exosome form (5) It is first diluted again to make it suitable for use. The subject of the invention is the use of exosomes primarily as a source in the production of personalized cosmetic products. The biological sample (1) to be used is provided. The biological sample (1) provided is cellular 25 It undergoes pre-treatment to remove residues and large particles. Pre- The processed biological sample (1) is isolated by means of the exosome isolation unit (2). It is subjected to this process. As a result of the insulation process, diameters in the range of approximately 30-150 nm are obtained. Isolated exosomes (3) are obtained. Isolation is performed by differential ultracentrifugation, membrane This can be achieved by filtration or size separation chromatography. Alternatively, 30 polymer-based precipitation, immuno-affinity-based separation, or microfluidic systems can be used. In addition to the methods mentioned, the insulation process can be carried out using similar methods for the same purpose. This can also be done using validated methods. The suspension containing the isolated exosomes (3) obtained as a result of isolation is subjected to purification process. is subjected to. In the preferred application, the purification process involves reducing the suspension to 0.22 µm 35 sterile filtration by passing the material through a membrane filter with a specific pore size. This is carried out in such a way that the microorganisms in the suspension are removed before lyophilization. This ensures the removal of contaminants and reduces the risk of biological contamination. After purification, isolated exosomes (3) are combined with cryoprotectant agent (4). A mixture is formed by bringing it in and subjecting it to lyophilization. Cryoprotectant agent (4), 5 Structural integrity and biological activity of isolated exosomes (3) during lyophilization An appropriate amount is added to the mixture to support its preservation. The resulting mixture It undergoes lyophilization under controlled temperature and pressure conditions. During lyophilization, the water content of the mixture is removed, resulting in a dry and stable lyophilized compound. exosome form (5) is obtained. In the preferred application of the invention, the stabilization process is 10 This is achieved through lyophilization. Alternative methods include spray drying and vacuum drying. Drying or various dehydration techniques can be used. The resulting lyophilized exosome form (5) is added to the cosmetic carrier matrix (6) It is distributed homogeneously. If necessary, at least one cosmetic carrier matrix (6) is added. Auxiliary active ingredient (7) is added. Lyophilized exosome form (5), cosmetic carrier 15 The matrix (6) and any auxiliary active ingredient (7) are mixed and subjected to homogenization. is retained and thus the final cosmetic product (8) suitable for topical application is obtained. In one application of the invention, the lyophilized exosome form (5) is used as a cosmetic carrier matrix (6) Auxiliary support systems can also be used to support its oscillation within. The subject is auxiliary carrier systems, lyophilized exosome form (5) cosmetic carrier matrix (6) 20 It can be configured to support controlled release within it. The resulting cosmetic product (8) may be rehydrated before use if deemed necessary. It is subjected to the process. In this process, rehydration liquid (9) is added to the final cosmetic product (8). It is added and mixed. Thus, the lyophilized exosome form (5) is re-added. It is diluted and the final cosmetic product (8) is made suitable for use. 25 The final cosmetic product (8), once ready for use, is applied topically to the skin surface or scalp. It is applied as follows. In this way, the final cosmetic product (8) is applied by injection or microneedling. This can be done without the need for invasive or micro-invasive procedures. The final cosmetic product (8); skin care, skin regeneration, anti-aging care, hair care and hair It can be used in cosmetic applications aimed at supporting follicle activation. 30 The invention deals with personalized cosmetic products and their production method, thereby enabling individual biological processes. A personalized cosmetic approach is offered that takes differences into account. The invention is biological. increasing the storability and portability of active content, improving ease of use and user experience. ensuring comfort and obtaining products that can be adapted to different cosmetic needs. It also enables the production method to be carried out in a controlled laboratory and production facility. 35 16 The fact that it can be carried out under these conditions, and that personalized cosmetic products are repeatable and It enables production in a standardized manner.
Claims
17 REQUESTS 1. A personalized product for topical application to the skin surface or scalp. cosmetic product (8) and its feature is; isolated exosomes (3) isolated from a biological sample (1) at least one obtained by lyophilizing in the presence of at least one cryoprotectant agent (4) lyophilized exosome form (5) and 5 within the aforementioned lyophilized exosome form (5) It contains at least one cosmetic carrier matrix (6) in which it is distributed.
2. According to Claim 1, it is a cosmetic product and its characteristic is that the biological sample mentioned (1) belongs to the individual. Peripheral blood is either plasma or serum.
3. According to claim 1, it is a cosmetic product and its characteristic is that the biological sample mentioned (1) is mesenchymal. It is the cell culture supernatant obtained from stem cell culture.
4. It is a cosmetic product according to claim 1, and its characteristic is that the isolated exosomes mentioned (3) are 30-150 nm diameter range. 15 5. It is a cosmetic product according to claim 1, and its characteristic is that the mentioned cryoprotectant agent (4) is trehalose, It must contain at least one of either sucrose or mannitol.
6. It is a cosmetic product according to claim 1, and its characteristic is that the mentioned cosmetic carrier matrix (6) 20 It can be in the form of a cream, serum, gel, lotion, or mask.
7. It is a cosmetic product according to claim 1, and its characteristic is that the mentioned cosmetic carrier matrix (6) The carrier system may be based on nanoparticles, contain a liposomal structure, or a hydrogel system.
8. It is a cosmetic product according to claim 1 and its characteristic is that it has at least one auxiliary active ingredient (7) It includes.
9. It is a cosmetic product according to claim 8, and its characteristic is that the aforementioned auxiliary active ingredient (7) Hyaluronic acid, peptide complexes, vitamin A, vitamin C, vitamin E, and antioxidant 30 It is the presence of at least one of the components.
10. It is a cosmetic product according to Claim 1, and its characteristic is that it contains the aforementioned lyophilized exosome form (5) It is used together with at least one rehydration liquid (9) for reconstitution. 35 18 11. The production method of a personalized cosmetic product (8) and its feature is; - removal of cellular debris and large particles from a biological sample (1) pre-processing for the purpose of - from the pre-processed biological sample (1) via an exosome isolation unit (2) 5 Obtaining isolated exosomes (3), - sterile filtration of the suspension containing isolated exosomes (3), - Mixing isolated exosomes (3) with at least one cryoprotectant agent (4), - The resulting mixture is subjected to lyophilization to form a lyophilized exosome. (5) obtaining, 10 - Addition of lyophilized exosome form (5) into at least one cosmetic carrier matrix (6) and - lyophilized exosome form (5) homogeneously in cosmetic carrier matrix (6) It includes the steps to obtain the final cosmetic product (8) by distributing it.
12. It is a production method according to claim 11, and its characteristic is that the isolated exosomes mentioned (3) differential ultracentrifugation, membrane filtration, or size separation chromatography It is obtained using at least one of these methods.
13. It is a production method according to Claim 11, characterized by; the aforementioned polymer-based precipitation, immune-20 obtained using at least one of the following: affinity-based separation or microfluidic systems. It is done.
14. It is a production method according to claim 11, and its characteristic is that the aforementioned sterile filtration process is 0.22 This is achieved using a membrane filter with a pore size of µm. 25 15. It is a production method according to claim 11, the characteristic of which is; lyophilized exosome form (5) cosmetic. After being added into the carrier matrix (6), at least one auxiliary active ingredient (7) Adding to the cosmetic carrier matrix (6) and subjecting the mixture to homogenization process It is an eclipse. 30 16. It is a production method according to claim 11, and its characteristic is that the final cosmetic product obtained (8) at least one rehydration liquid (9) must be added and mixed before use. This is the reconstitution of the lyophilized exosome form (5). 35